Diarrhea News and Research

Latest Diarrhea News and Research

AJG publishes new review on Inflammatory Bowel Disease management

The American College of Gastroenterology published a new evidence-based systematic review on the management of Inflammatory Bowel Disease as a supplement to The American Journal of Gastroenterology for April 2011, a special issue entirely dedicated to IBD.

8 Apr 2011

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.

7 Apr 2011

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.

7 Apr 2011

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.

6 Apr 2011

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID, in the United States.

6 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

Cubist Pharmaceuticals, Inc. today announced that it has entered into a license agreement with Teva Parenteral Medicines, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., which includes a stipulation by the parties requesting dismissal of the lawsuit filed by Cubist in the U.S. District Court for the District of Delaware relating to the Abbreviated New Drug Application filed by TPM with the U.S. Food and Drug Administration for a generic version of CUBICIN.

5 Apr 2011

South Asian Conference on Sanitation kicks off in Sri Lanka

The fourth South Asian Conference on Sanitation kicked off Monday in the Sri Lankan capital city of Colombo, to raise awareness about the "sanitation crisis in the region," Xinhua reports.

5 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer Pharmaceuticals, Inc. announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection.

4 Apr 2011

Positive results from GDC-0973, GDC-0941 combination therapy Phase I trial against cancer

The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

Optimer reports grant of inducement stock options

Optimer Pharmaceuticals, Inc. announced today that on March 31, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 258,000 shares of common stock to 7 new employees.

2 Apr 2011

Lilly's Axiron testosterone replacement therapy now available in US pharmacies

Eli Lilly and Company announced today that Axiron® (testosterone) topical solution is available in pharmacies throughout the United States. Axiron is a prescription medicine used to treat adult males that have low or no testosterone. Safety and efficacy of Axiron in males younger than 18 years of age have not been established.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

EPA approves Clorox DISPATCH disinfectant towels registration to fight against C. difficile

The Clorox Company announced today that the U.S. Environmental Protection Agency approved the registration of DISPATCH Hospital Cleaner Disinfectant Towels with Bleach to kill Clostridium difficile spores in five minutes, the fastest C. difficile contact time available.

31 Mar 2011

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).

31 Mar 2011

Diarrhea News and Research

Latest Diarrhea News and Research

AJG publishes new review on Inflammatory Bowel Disease management

Shionogi launches CUVPOSA for pediatric chronic severe drooling

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

Lupin grants Salix exclusive worldwide rights to rifaximin

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

South Asian Conference on Sanitation kicks off in Sri Lanka

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Positive results from GDC-0973, GDC-0941 combination therapy Phase I trial against cancer

Optimer reports grant of inducement stock options

Lilly's Axiron testosterone replacement therapy now available in US pharmacies

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Vertex announces final results from Phase 3 REALIZE study against HCV

EPA approves Clorox DISPATCH disinfectant towels registration to fight against C. difficile

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in